National Bank of Canada
TPST icon

National Bank of Canada’s Tempest Therapeutics TPST Stock Holding History

National Bank of Canada’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,538
Closed -$10.4K – 3223
2025
Q2 		$10.4K Hold
1,538
– – ﹤0.01% 2349
2025
Q1 		$14.7K Buy
1,538
+769
+100% +$8.72K ﹤0.01% 2151
2024
Q4 		$8.35K Buy
+769
New +$9.93K ﹤0.01% 2374

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $84.4B AUM 52.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

National Bank of Canada's TPST Position: Q3 2025 in Review

National Bank of Canada sold out of Tempest Therapeutics (TPST) in Q3 2025, closing a stake of 1,538 shares — an estimated $10.4K sold.

National Bank of Canada first reported a position in TPST in Q4 2024 and held it in 3 quarters. The position peaked at $14.7K in Q1 2025. 17 funds tracked by Wall St. Rank hold TPST as of Q3 2025.

  • National Bank of Canada reported no remaining Tempest Therapeutics position as of Q3 2025 after selling out during the quarter.
  • National Bank of Canada sold 1,538 Tempest Therapeutics shares in Q3 2025, an estimated $10.4K.
  • National Bank of Canada first reported a position in Tempest Therapeutics in Q4 2024 and held it in 3 quarters.
  • National Bank of Canada's Tempest Therapeutics position peaked at $14.7K in Q1 2025.
  • 17 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2025.

Based on National Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.